Elevatus Welath Management Vertex Pharmaceuticals Inc Put Options Transaction History
Elevatus Welath Management
- $267 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding VRTX
# of Institutions
1,719Shares Held
225MCall Options Held
1.19MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$12.6 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.9 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.1 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.54 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.04 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $121B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...